Menu Search
Equities

Xvivo Perfusion AB

XVIVO:STO

Xvivo Perfusion AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)451.50
  • Today's Change5.50 / 1.23%
  • Shares traded42.31k
  • 1 Year change+69.74%
  • Beta2.0290
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in SEK

The 5 analysts offering 12 month price targets for Xvivo Perfusion AB have a median target of 560.00, with a high estimate of 584.00 and a low estimate of 480.00. The median estimate represents a 24.03% increase from the last price of 451.50.
High29.3%584.00
Med24.0%560.00
Low6.3%480.00

Dividends in SEK

Dividend information is not available for Xvivo Perfusion AB.
Div growth (TTM)--
More ▼

Earnings history & estimates in SEK

On Oct 24, 2024, Xvivo Perfusion AB reported 3rd quarter 2024 earnings of 2.71 per share. This result exceeded the 0.68 consensus of the 4 analysts covering the company and exceeded last year's 3rd quarter results by 2.63.
The next earnings announcement is expected on Jan 28, 2025.
Average growth rate+694.21%
Xvivo Perfusion AB reported annual 2023 earnings of 3.07 per share on Jan 25, 2024.
Average growth rate+127.44%
More ▼

Revenue history & estimates in SEK

Xvivo Perfusion AB (publ) had 3rd quarter 2024 revenues of 198.48m. This missed the 208.25m consensus estimate of the 4 analysts following the company. This was 41.15% above the prior year's 3rd quarter results.
Average growth rate+8.28%
Xvivo Perfusion AB (publ) had revenues for the full year 2023 of 597.54m. This was 43.88% above the prior year's results.
Average growth rate+32.43%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.